Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen
نویسندگان
چکیده
منابع مشابه
Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen
BACKGROUND/AIMS At our hemodialysis (HD) unit, we noted a drop in the treatment dose of erythropoietin-stimulating agents (ESAs) when the frequency of dose adjustment was reduced from weekly, where doses were withheld if hemoglobin was >130 g/l, to monthly, where doses were not withheld. The aim of this study was to find an explanation for this reduction in ESA requirement. METHODS This is a ...
متن کاملShould erythropoiesis-stimulating agents be used in predialysis patients?
Anemia results from insufficient production of erythropoietin by the kidneys and is a common complication of chronic kidney disease. It is present in most patients with stage 4 and 5 chronic kidney disease. Studies have linked untreated anemia in chronic kidney disease to worsening cardiovascular complications, possible acceleration to end-stage renal disease, and death. Administration of eryth...
متن کاملNovel erythropoiesis-stimulating agents: a new era in anemia management.
Nearly two decades ago, recombinant human erythropoietin transformed the management of chronic kidney disease anemia by allowing a more sustained increase in hemoglobin than was possible by intermittent blood transfusion. The treatment was highly effective, but because of the fairly short half-life of the molecule at approximately 6 to 8 h, injections usually had to be administered two to three...
متن کاملLess frequent dosing of erythropoiesis stimulating agents in patients undergoing dialysis: a European multicentre cost study.
OBJECTIVE To calculate the variable costs involved with the process of delivering erythropoiesis stimulating agents (ESA) in European dialysis practices. METHODS A conceptual model was developed to classify the processes and sub-processes followed in the pharmacy (ordering from supplier, receiving/storing/delivering ESA to the dialysis unit), dialysis unit (dose determination, ordering, recei...
متن کاملExtended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
The recombinant human erythropoietins epoetins alfa and beta have relatively short half-lives ( approximately 24 h by subcutaneous route) and have traditionally been administered 2 or 3 times a week for the treatment of anaemia in patients with chronic kidney disease. However, multiple weekly injections are inconvenient for both the patient and the healthcare provider. With the introduction of ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nephron Extra
سال: 2011
ISSN: 1664-5529
DOI: 10.1159/000329889